Quartuccio, L., Sonaglia, A., Pecori, D., Peghin, M., Fabris, M., Tascini, C., & De Vita, S. (2020). Higher levels of IL‐6 early after tocilizumab distinguish survivors from nonsurvivors in COVID‐19 pneumonia: A possible indication for deeper targeting of IL‐6. J Med Virol.

Quartuccio, Luca, Arianna Sonaglia, Davide Pecori, Maddalena Peghin, Martina Fabris, Carlo Tascini, et Salvatore De Vita. "Higher Levels of IL‐6 Early After Tocilizumab Distinguish Survivors From Nonsurvivors in COVID‐19 Pneumonia: A Possible Indication for Deeper Targeting of IL‐6." J Med Virol 2020.

Quartuccio, Luca, et al. "Higher Levels of IL‐6 Early After Tocilizumab Distinguish Survivors From Nonsurvivors in COVID‐19 Pneumonia: A Possible Indication for Deeper Targeting of IL‐6." J Med Virol 2020.